<DOC>
	<DOC>NCT00144456</DOC>
	<brief_summary>A prospective, randomized, double-blind study to compare the effect of ED-71 with that of alfacalcidol on fracture incidence</brief_summary>
	<brief_title>A New Active Vitamin D, ED-71 for Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Osteoporotic patients who meet any of the following condition: 1. with at least one fragility fracture, 2. above 70 yearold with bone mineral density below 70% young adult mean, 3. with bone mineral density below 60% young adult mean Women three years or more after menopause or men Current disorders such as primary hyperparathyroidism, Cushing's syndrome,gonadal insufficiency, poorly controlled diabetes mellitus or other causes of secondary osteoporosis A history or suspicion of active urolithiasis at any time Use of bisphosphonates in the past 12 months Use of medications known to affect bone in the past 2 months Abnormal serum calcium, urinary calcium, serum creatinine or liver function tests</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>